Keywords: Alzheimer, Prana Biotechnology, PBT2, neurological diseases

Prana gains patent protection for its PBT2 in Europe

Article | 05 August 2009

Australia’s Prana Biotechnology has secured a key patent protecting its clinical drug asset PBT2, with the European Patent Office ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in